Naslov
Evaluating extended-release calcifediol as a treatment option for chronic kidney disease- mineral and bone disorder (CKD-MBD)

Autori
Cozzolino, Mario ; Ketteler, Markus

Izvornik
Expert Opinion on Pharmacotherapy (1465-6566) 20 (2019), 17; 2081-2093

Vrsta, podvrsta i kategorija rada
Radovi u časopisima, uvodnik, stručni

Ključne riječi
Extended-release calcifediol ; ERC ; non-dialysis-chronic kidney disease

Sažetak
Introduction: Extended-release calcifediol (ERC) is an orally administered prohormone of active vitamin D (1, 25-dihydroxyvitamin D [1, 25D]) designed to safely and sufficiently increase serum total 25-hydroxyvitamin D (25D) to reduce elevated parathyroid hormone (PTH) in patients with non- dialysis-chronic kidney disease (ND-CKD). ERC is currently approved in the United States and Canada. Areas covered: Herein, key clinical data relating to the pharmacokinetics, pharmacodynamics, efficacy and safety of ERC are reviewed. Expert opinion: Currently available treatment options for secondary hyperparathyroidism (SHPT) in ND-CKD have limitations: the effectiveness of nutritional vitamin D supplements for reduction of PTH levels is unproven and active (1 alpha-hydroxylated) vitamin D analogues elevate serum calcium, which increases the risk of hypercalcemia and vascular calcification. Clinical studies show that ERC is an effective, well tolerated treatment for SHPT in ND-CKD. ERC gradually raises serum 25D levels, resulting in physiologically regulated increases in serum 1, 25D and sustained reductions in PTH, while avoiding clinically meaningful increases in serum phosphorus, calcium and fibroblast growth factor 23. ERC offers a new, effective and well tolerated treatment option for the early management of SHPT in patients with ND-CKD.

Izvorni jezik
Engleski

Znanstvena područja
Kliničke medicinske znanosti

POVEZANOST RADA